| Full Name | GLI Family Zinc Finger 2 |
| Gene Symbol | GLI2 |
| Chromosomal Location | 2q14.2 |
| NCBI Gene ID | [2736](https://www.ncbi.nlm.nih.gov/gene/2736) |
| OMIM | [165230](https://omim.org/entry/165230) |
| Ensembl | [ENSG00000074047](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000074047) |
| UniProt (Protein) | [P10070 (GLI2)](https://www.uniprot.org/uniprot/P10070) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Holoprosencephaly, Medulloblastoma, [Huntington's Disease](/diseases/huntingtons-disease) |
GLI2 (GLI Family Zinc Finger 2) encodes a 1586 amino acid zinc finger transcription factor that functions as the primary transcriptional activator of the Hedgehog (Hh) signaling pathway. GLI2 integrates signals from Smoothened (SMO) and Suppressor of Fused (SUFU) to regulate target gene expression essential for neural development, adult neurogenesis, and neuronal survival. In contrast to GLI1, which acts exclusively as a transcriptional activator, GLI2 possesses both activator and repressor domains, making it the primary effector that converts graded Hedgehog signals into differential transcriptional outputs. Dysregulation of GLI2 contributes to neurodegenerative disease, developmental brain malformations, and brain tumors.
GLI2 spans approximately 264 kb on chromosome 2q14.2 and contains 13 exons encoding a 1586 amino acid protein. The gene produces multiple transcript variants through alternative splicing and alternative promoter usage, including a truncated N-terminal repressor form (GLI2ΔN) that lacks the activation domain. The promoter contains binding sites for SOX, POU, and Hedgehog-responsive elements that mediate autoregulatory feedback.
In the developing central nervous system, GLI2 is highly expressed in the ventral neural tube floor plate, where it is essential for specification of ventral cell fates including dopaminergic progenitors of the midbrain. In the adult brain, GLI2 expression persists in neurogenic niches — the subventricular zone (SVZ) and the hippocampal subgranular zone (SGZ) — and is maintained in astrocytes, cerebellar granule neurons, and oligodendrocyte precursor cells. The Allen Brain Atlas shows broad expression across cortical regions with enrichment in the cerebellum, hippocampus, and thalamus.
GLI2 is a bifunctional zinc finger transcription factor containing five tandem C2H2 zinc finger domains that bind the consensus DNA sequence 5'-GACCACCCA-3' in target gene promoters. The protein is organized into distinct functional domains:
In the absence of Hedgehog ligand, SUFU binds GLI2 in the cytoplasm and promotes its partial proteolytic processing by the proteasome into a truncated N-terminal repressor form (GLI2R). This processing requires sequential phosphorylation by PKA, GSK3β, and CK1 kinases, which create a phosphodegron recognized by the β-TrCP/SCF E3 ubiquitin ligase complex. Upon Hedgehog pathway activation, SMO triggers dissociation of the SUFU-GLI2 complex at the tip of the primary cilium, stabilizing full-length GLI2 activator (GLI2A) that translocates to the nucleus to drive target gene transcription.
Key transcriptional targets of GLI2 include GLI1 (positive feedback amplifier), PTCH1 (negative feedback receptor), PTCH2, HHIP, MYCN, CCND1, FOXM1, and BCL2. GLI2 is the essential activator for floor plate induction, dopaminergic neuron specification, and cerebellar development.
GLI2 expression is reduced in the hippocampus and entorhinal cortex of Alzheimer's Disease (AD) patients. Diminished Hedgehog-GLI2 signaling impairs adult hippocampal neurogenesis, contributing to cognitive decline. In APP/PS1 transgenic mice, pharmacological activation of the Hedgehog pathway with SMO agonists restores GLI2 nuclear translocation, enhances neurogenesis in the SGZ, and improves spatial memory performance. GLI2 target genes including MYCN and CCND1 regulate neural progenitor proliferation, and their downregulation correlates with reduced dentate gyrus volume in AD.
GLI2 is critical for the specification and survival of midbrain dopaminergic neurons in the substantia nigra. During development, GLI2 cooperates with FOXA2 and LMX1A to establish the dopaminergic progenitor domain. In Parkinson's Disease (PD), reduced Hedgehog pathway activity and decreased GLI2 nuclear localization have been observed in surviving nigral neurons. Conditional deletion of GLI2 in dopaminergic neurons accelerates their degeneration in MPTP-treated mice. GLI2-dependent expression of BDNF, GDNF, and anti-apoptotic factors provides autocrine neuroprotective signaling that is compromised in PD.
In Huntington's Disease (HD), mutant huntingtin protein disrupts primary cilium structure and function, impairing cilium-dependent GLI2 processing and activation. R6/2 and zQ175 HD mouse models show reduced GLI2 activator levels and impaired Hedgehog target gene expression in striatal medium spiny neurons. Restoration of ciliary function or direct GLI2 activation partially rescues striatal neuron survival in these models.
Heterozygous loss-of-function mutations in GLI2 cause holoprosencephaly (HPE) type 9 (HPE9, OMIM 610829), a spectrum of forebrain midline developmental defects. GLI2-associated HPE ranges from severe alobar HPE with cyclopia to milder microforms with hypopituitarism. Over 40 pathogenic variants have been identified, predominantly truncating mutations in the zinc finger domain or activation domain. Penetrance is incomplete, suggesting modifier gene interactions with SHH, SIX3, and ZIC2.
| Variant | Type | Clinical Significance |
|---|---|---|
| c.1681C>T (p.Arg561Ter) | Nonsense | Holoprosencephaly 9 (pathogenic) |
| c.680delG | Frameshift | Holoprosencephaly 9 (pathogenic) |
| c.2554C>T (p.Arg852Cys) | Missense | Pituitary anomalies (likely pathogenic) |
| rs11688767 | Intronic SNP | Associated with hippocampal volume in GWAS |
| c.4111G>A (p.Glu1371Lys) | Missense | VUS, activation domain |
GLI2 is a key pharmacological target at the convergence of Hedgehog signaling and neuroprotection: